Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 TiGenix Opens U.S. Headquarters | Contract Pharma

What are you searching for?

Sign in
Breaking News

TiGenix Opens U.S. Headquarters

Will support efforts to develop and commercialize its lead product, Cx601, in the U.S.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

TiGenix NV, a biopharma company focused on developing therapies leveraging anti-inflammatory properties of allogeneic, or donor-derived, stem cells, has opened a U.S. office in Cambridge, MA. Establishing U.S. operations will support its strategic goal of developing and commercializing its lead product, Cx601, for the treatment of complex perianal fistulas in Crohn’s disease patients, in the U.S.

The U.S. operations are based at the Cambridge Innovation Center in Kendall Square, at the epicenter of the Boston-area biotech hub. TiGenix is in the process of appointing a senior team to support the U.S. and Canadian launch of its global Phase III trial for Cx601. 

TiGenix anticipates initiating patient recruitment for the trial in North American centers in 1H18. The global trial is designed to support a future U.S. Biologics License Application (BLA) to the FDA.

Eduardo Bravo, chief executive officer of TiGenix said, “It is very exciting to be establishing TiGenix at the heart of one of the world’s leading biotechnology hubs. We are working hard to progress the development of Cx601 in the U.S. and having a team based in Cambridge will add further momentum to these efforts to bring a new treatment option to U.S patients suffering from this severe and debilitating complication of Crohn’s disease.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics